TING-YUAN LANLin, Yen-ChunYen-ChunLinTAI-CHUNG TSENGHUNG-CHIH YANGJUI-HUNG KAOCHIAO-FENG CHENGLee, Tai-JuTai-JuLeeSHANG-CHIN HUANGKO-JEN LICHENG-HSUN LUSONG-CHOU HSIEH2022-11-092022-11-0920231976-2283https://scholars.lib.ntu.edu.tw/handle/123456789/624525Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate in hepatitis B surface antigen (HBsAg)-negative patients receiving rituximab for autoimmune diseases in a large real-world cohort.enAutoimmune diseases; Hepatitis B; Rituximab[SDGs]SDG3Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areasjournal article10.5009/gnl21055136268584WOS:000877095300001